All In Biotech

Drug Trial Radar · NCT03778073

Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

A Phase 1 Study of Cosibelimab (TG-1501) in Subjects With Relapsed or Refractory Lymphoma

Last checked: Nov 20, 2026Latest source record: Aug 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

18

Actual

Start

Apr 17, 2019

Primary completion

May 3, 2022

Study completion Aug 1, 2022

Sponsor

Lead sponsor
TG Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.

Conditions

  • B-cell Non Hodgkin Lymphoma
  • Richter's Transformation

Interventions

  • CosibelimabDrug

    Intravenous infusion on Days 1 and 15 of every 28-day cycle or only on Day 1 of every 28-day cycle

  • Cosibelimab + Ublituximab + Bendamustine combinationDrug

    Cosibelimab (Intravenous infusion): Cycle 1-6 Days 1\&15, Cycles 7-12 Day 1, Cycles 15-24 Day 1 every 3 cycles; Ublituximab (Intravenous infusion): Cycles 1-6 Day 1, Cycles 9-24 every 3 Cycles; Bendamustine (Intravenous infusion): Cycle 1 Days 2\&3, Cycles 2-6 Days 1\&2.

  • Cosibelimab + Ublituximab + Bendamustine combinationDrug

    Cosibelimab (Intravenous infusion): Cycle 1-12 Day 1, Cycles 15-24 Day 1 every 3 cycles; Ublituximab (Intravenous infusion): Cycles 1-6 Day 1, Cycles 9-24 every 3 Cycles; Bendamustine (Intravenous infusion): Cycle 1 Days 2\&3, Cycles 2-6 Days 1\&2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events That Are Related to TreatmentTime frame: 6 months of therapy

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • TG Therapeutics Investigational Trial Site

    Huntsville, Alabama

  • TG Therapeutics Investigational Trial Site

    Tucson, Arizona

  • TG Therapeutics Investigational Trial Site

    Fayetteville, Arkansas

  • TG Therapeutics Investigational Trial Site

    Peoria, Illinois

  • TG Therapeutics Investigational Trial Site

    Fort Wayne, Indiana

  • TG Therapeutics Investigational Trial Site

    Fairway, Kansas

  • TG Therapeutics Investigational Trial Site

    Louisville, Kentucky

  • TG Therapeutics Investigational Trial Site

    Charlotte, North Carolina

  • TG Therapeutics Investigational Trial Site

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.